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Abstract
Introduction: Ankylosing spondylitis (AS) is characterized by excessive bone formation and bone loss. Our aim was to
investigate the association of bone turnover markers (BTM) with spinal radiographic damage and bone mineral density
(BMD) in AS patients with active disease.
Methods: 201 consecutive AS outpatients of the Groningen Leeuwarden AS (GLAS) cohort were included. Serum markers of
bone resorption (C-telopeptides of type-I collagen, sCTX) and bone formation (procollagen type-I N-terminal peptide, PINP;
bone-specific alkaline phosphatase, BALP) were measured. Z-scores were used to correct for the normal influence that age
and gender have on bone turnover. Radiographs were scored by two independent readers according to modified Stoke AS
Spinal Score (mSASSS). The presence of complete bridging (ankylosis of at least two vertebrae) was considered as measure
of more advanced radiographic damage. Low BMD was defined as lumbar spine and/or hip BMD Z-score # 21.
Results: Of the 151 patients with complete data, 52 (34%) had $1 complete bridge, 49 (33%) had$1 syndesmophyte (non-
bridging), and 50 (33%) had no syndesmophytes. 66 (44%) had low BMD. Patients with bridging had significantly higher
sCTX and PINP Z-scores than patients without bridging (0.43 vs. 20.55 and 0.55 vs. 0.04, respectively). Patients with low
BMD had significantly higher sCTX Z-score than patients with normal BMD (20.08 vs. 20.61). After correcting for gender,
symptom duration, and CRP, sCTX Z-score remained significantly related to the presence of low BMD alone (OR: 1.60),
bridging alone (OR: 1.82), and bridging in combination with low BMD (OR: 2.26).
Conclusions: This cross-sectional study in AS patients with active and relatively long-standing disease demonstrated that
higher serum levels of sCTX, and to a lesser extent PINP, are associated with the presence of complete bridging. sCTX was
also associated with low BMD. Longitudinal studies are needed to confirm that serum levels of sCTX can serve as objective
marker for bone-related outcome in AS.
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Introduction
Ankylosing spondylitis (AS) is an autoinflammatory rheumatic
disease that predominantly affects the axial skeleton. The disease is
characterized by the combination of inflammation, new bone
formation, and bone loss. Spinal radiographic outcome related to
excessive bone formation, so called osteoproliferation, comprises
the formation of syndesmophytes with as final outcome complete
bridging (ankylosis of two vertebrae). Eventually, complete fusion
of the entire vertebral column can result in a so-called ‘bamboo
spine’. [1,2] The natural course of the disease can vary from mild
to severe axial involvement and from slow to rapid radiographic
progression. [1,3] The presence of syndesmophytes at study entry
is the most important predictor for the development of more
extensive radiographic damage. [1,3,4] Furthermore, male gender,
longer disease duration, smoking, human leukocyte antigen
(HLA)-B27 positivity, and increased inflammatory markers were
found to be related to spinal osteoproliferation.[5–7].
On the other hand, excessive bone loss can lead to osteopenia
and osteoporosis, assessed by bone mineral density (BMD), which
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can already be observed at early stages of the disease. Severe
vertebral bone loss may lead to vertebral fractures with increased
spinal deformity. [8,9] The presence of inflammation, low serum
vitamin D levels, medication use, and decreased mobility related to
pain, stiffness, and radiographic damage may contribute to bone
loss in AS patients.[10–13].
There is a clear need for biomarkers reflecting bone-related
outcome, which can help physicians in the process of decision-
making on the management of AS. Previous studies in AS reported
that higher serum levels of matrix metalloproteinase-3 (MMP-3), a
marker of tissue remodeling, as well as lower serum levels of
sclerostin and dickkopf-1, both regulators of bone turnover, were
significantly associated with 2-year radiographic progression of the
spine.[14–16] Furthermore, a relation was found between a
biochemical marker of type II collagen degradation (urinary CTX-
II, reflecting cartilage turnover) and increased radiographic
damage or 2-year progression. [17,18] These studies also showed
a relation between a biochemical marker of type I collagen
degradation (urinary CTX-I, reflecting bone resorption) and lower
BMD at the hip. [17,18] In one of our previous studies, we
demonstrated that higher serum levels of CTX-I are associated
with bone loss in AS patients with active disease. [11].
Bone turnover markers (BTM) may serve as objective markers
for bone-related outcome in AS. A challenge of working with
BTM is that serum levels change with age and there are
differences for gender. Our healthy reference cohort on BTM
enables us to correct BTM levels of individual AS patients for the
normal influence that age and gender have on bone turnover. The
aim of the present cross-sectional study was to investigate the
association of BTM with spinal radiographic damage and BMD in
AS patients with active disease.
Methods
Patients
Data collected before start of tumor necrosis factor-alpha (TNF-
a) blocking therapy were used from 201 consecutive AS patients
included in the Groningen Leeuwarden Ankylosing Spondylitis
(GLAS) cohort [19] between November 2004 and December
2010. Patients with recent fractures or use of bisphosphonates
were excluded because of their major influence on the bone
metabolism. All patients were over 18 years of age, fulfilled the
modified New York criteria for AS, [20] and had active disease
defined by Bath AS Disease Activity Index (BASDAI) $4 (range
0–10) or based on expert opinion. [21].
Ethics Statement
The study was approved by the local ethics committees of the
Medical Center Leeuwarden (MCL) and University Medical
Center Groningen (UMCG). All patients provided written
informed consent according to the Declaration of Helsinki to
participate in this study.
BTM Assessments
Bone turnover was studied by assessment of bone resorption
marker serum cross-linked telopeptide of type-I collagen (sCTX)
and bone formation markers procollagen type-I N-terminal
peptide (PINP) and bone-specific alkaline phosphatase (BALP).
sCTX was measured by electrochemiluminescence immunoassay
(ECLIA; Elecsys 2010 Roche Mannheim, Germany; inter-assay
coefficient of variation (IE-CV) 10.8%), PINP by radioimmuno-
assay (RIA; Orion Diagnostica, Espoo, Finland; IE-CV 9.0%), and
BALP by enzyme-linked immunosorbent assay (ELISA; Metra
Biosystems, Mountain View, CA, USA; IE-CV 5.5%). Serum
samples were stored at 220uC until analysis.
BTM Z-scores, the number of standard deviations (SD) from the
normal mean corrected for age and gender, were calculated using
a Dutch reference group (200 men and 350 women) checked for
serum 25-hydroxyvitamin D levels .50 nmol/liter as well as for
the absence of osteoporosis (BMD T-score .22.5) after 50 years
of age. Z-scores were calculated as follows: (BTM value of
individual patient – mean BTM value of matched 10-year-cohort
of reference group)/SD of matched reference cohort.
Radiological Assessments
The lateral view of radiographs of the cervical and lumbar spine
were blinded for patient characteristics and were scored according
to the modified Stoke AS Spinal Score (mSASSS) by two trained
readers (SA and AS) independent from each other. The anterior
corners of lower C2 until upper T1and lower T12 until upper S1
were scored for the presence of erosions, sclerosis, and/or squaring
(1 point per site), syndesmophytes (without ankylosis of vertebrae;
2 points per site), and complete bridging (ankylosis of two
vertebrae; 3 points per site). The mSASSS was calculated as the
sum of the scores at all individual sites (range 0–72). In case #3
vertebral sites were missing, these values were substituted by the
mean score of the vertebrae of the same spinal segment. If .3
vertebral sites were missing, the patient was excluded from analysis
(n = 6). If the mSASSS total score of both readers differed by .5
units, the X-ray was reread by the same readers. When the
discrepancy of .5 units persisted following rereading, consensus
was reached. [22,23] The average mSASSS total score of both
readers was used for analysis.
Inter-observer reliability for mSASSS was very good. The
intraclass correlation coefficient (two-way random effects model,
single measures, absolute agreement) before consensus was 0.985
(95% confidence interval (CI): 0.979–0.990). Bland-Altman
analyses showed that the mean difference in mSASSS between
both readers was small (0.7). The 95% limits of agreement were
between 25.6 and 7.1, out of a total of 72.
The presence or absence of syndesmophytes and complete
bridging was analyzed as measure of definite radiographic
damage. Agreement between readers was very good, with Cohen’s
kappa of 0.88 (0.80–0.96) for the presence of syndesmophytes and
0.91 (0.84–0.98) for the presence of bridging. In case of
discrepancy between both readers, the consensus score was used
for analysis.
BMD Measurement
BMD at the lumbar spine (anterior-posterior projection at L1-
L4) and hip (total proximal femur) were measured using DXA
(Hologic QDR Discovery (UMCG) or Hologic QDR Delphi
(MCL), Waltman, MA, USA). Z-scores were calculated using the
NHANES reference database. Low BMD was defined as lumbar
spine and/or hip BMD Z-score # 21. The International Society
for Clinical Densitometry recommends using BMD Z-scores
instead of BMD T-scores in premenopausal women and men
under the age of 50. [24].
Clinical Assessments
Demographic data including smoking status, symptom duration,
year of diagnosis, HLA-B27 status, history of extra-articular
manifestations, presence of peripheral arthritis (defined as $1
swollen joint), and use of nonsteroidal anti-inflammatory drugs
(NSAIDs) and disease-modifying antirheumatic drugs (DMARDs)
were collected. Disease activity was assessed using BASDAI, [25]
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
Bone Turnover as Marker for Disease Outcome in Ankylosing Spondylitis
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and AS disease activity score (ASDAS) calculated from BASDAI
questions 2, 3, and 6, patient’s global assessment of disease activity,
and CRP. [26,27] Physical function was assessed using Bath AS
Functional Index (BASFI; on a scale of 0–10). [28].
Clinical visits including biobanking and radiological and BMD
measurements were performed within one year (median difference
1.6 and 0.3 months, respectively).
Statistical Analysis
Patients with complete data available on BTM, radiology, and
BMD were used in all analyses. Results were expressed as mean 6
SD or median (range) for normally distributed and non-normally
distributed data, respectively. Independent samples t test, Mann-
Whitney U test, and Chi-Square test were used to compare
differences in patient characteristics between groups.
For BTM comparisons, Kruskal-Wallis test and Mann-Whitney
U test were used. Univariable logistic regression was performed to
analyze the relation between BTM Z-scores and the presence or
absence of complete bridging and low or normal BMD.
Multivariable logistic regression was performed to correct these
relations for other variables that were significantly different
between these patient groups. Finally, multinomial regression
was used for the combined analysis of the presence of bridging and
low BMD. Patients without bridging plus normal BMD were used
as reference category.
Receiver operating characteristic (ROC) analysis was performed
to determine the accuracy of BTM Z-scores to discriminate
between patients with or without bridging and low or normal
BMD. Area under the curve (AUC) ,0.70 was interpreted as poor
accuracy, 0.70, AUC ,0.90 as moderate accuracy, and AUC .
0.90 as high accuracy. [29].
Spearman’s correlation coefficient (r) was used to analyze the
relation between BTM Z-scores and mSASSS. P values ,
0.05 were considered statistically significant. Statistical analysis
was performed with IBM SPSS Statistics 20 (SPSS, Chicago, IL,
USA).
Table 1. Characteristics of the AS study population (n = 151).
Gender (male) (n, %) 108 (72)
Age (yrs) 42.1611.4
Duration of symptoms (yrs) 15 (1–53)
Time since diagnosis (yrs) 7 (0–44)
HLA-B27+ (n, %) 120 (82)
History of IBD (n, %) 14 (9)
History of uveitis (n, %) 44 (29)
History of psoriasis (n, %) 9 (6)
Peripheral arthritis (n, %) 29 (19)
Current smoking (n, %){ 45 (41)
Current NSAID use (n, %) 108 (72)
Current DMARD use (n, %) 36 (24)
Current steroid use (n, %)` 11 (7)
BASDAI (range 0–10) 6.161.7 BASDAI $4 (n, %)* 135 (89)
ASDASCRP 3.860.8 ASDASCRP$2.1 (n, %)* 146 (99)
ESR (mm/h) 21 (2–90)
CRP (mg/l) 13 (2–99)
BASFI (range 0–10) 5.7 (0.4–9.7)
sCTX Z-score 20.34 (22.58–5.38)
PINP Z-score 0.23 (21.75–8.77)
BALP Z-score 0.32 (22.59–10.38)
mSASSS (range 0–72) 12 (1–72) $1 syndesmophyte (n, %) 101 (67)
$1 complete bridge (n, %) 52 (34)
LS BMD Z-score –0.3361.49 LS BMD Z-score #–1 (n, %) 52 (36)
LS BMD Z-score #–2 (n, %) 16 (11)
Hip BMD Z-score –0.2361.06 Hip BMD Z-score #–1 (n, %) 38 (25)
Hip BMD Z-score #–2 (n, %) 6 (4)
Values are mean 6 SD or median (range) unless otherwise indicated.
{Data were available in 72% of the patients.
`Of these patients, 3 used systemic corticosteroids (prednison 5 mg/d n = 2, budenofalk 6 mg/d n = 1) and 8 used local corticosteroids (nose drops n = 3, eye drops
n= 2, inhaled n = 2, skin cream n= 1, injection knee n = 1).
*Active disease based on BASDAI (21) or ASDAS [37].
AS, ankylosing spondylitis; HLA-B27+, human leukocyte antigen B27 positive; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; DMARD,
disease-modifying antirheumatic drug; BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive
protein; BASFI, Bath AS functional index; PINP, procollagen type I N-terminal peptide; BALP, bone-specific-alkaline phosphatase; sCTX, serum C-telopeptide of type I
collagen; mSASSS, modified stoke AS spinal score; LS, lumbar spine; BMD, bone mineral density.
doi:10.1371/journal.pone.0099685.t001
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Results
In total, 151 of 201 AS patients (75%) had complete data
available on BTM, radiology, and BMD. Of these patients, mean
age was 42.1 years (SD 611.4), median symptom duration was 15
years (range 1–53), and 72% were male (Table 1). Patient
characteristics were comparable between patients with and
without complete data, except for BASFI score (5.7 vs. 6.4,
p = 0.048).
Radiological Damage and BTM
Of the 151 patients, 52 (34%) had at least one complete bridge,
49 (33%) had at least one syndesmophyte (non-bridging), and 50
(33%) had no syndesmophytes. Patients with bridging had
significantly higher sCTX and PINP Z-scores than patients with
non-bridging syndesmophytes or without syndesmophytes, where-
as no significant difference was found in BALP Z-score (Figure 1).
No significant differences in BTM Z-scores were found between
patients with and without non-bridging syndesmophytes (Figure 1)
and these two categories were combined in further analyses. The
presence of complete bridging was considered as measure of more
advanced radiographic damage. In these patients, the median
number of bridges was 4 (range 1–12). The median difference in
Z-score between patients with (n = 52) and without (n = 99)
bridging was larger for sCTX than for PINP (0.98 vs. 0.51). In
addition, patients with bridging were significantly more often male
and had more long-standing disease (Table 2).
In univariable logistic regression, sCTX Z-score (odds ratio
(OR): 1.62, 95% CI: 1.22–2.14) and PINP Z-score (OR: 1.43,
1.06–1.93) were significantly associated with the presence of
complete bridging. The amount of variance explained by sCTX
and PINP was 11.6% and 5.5%, respectively. ROC analysis
showed that the AUC discriminating between patients with and
without bridging was 0.66 (0.57–0.75) for sCTX Z-score and 0.64
(0.55–0.73) for PINP Z-score. After correcting for gender and
symptom duration, sCTX Z-score (OR: 1.50, 1.09–2.07) remained
significantly related to the presence of bridging, while PINP Z-
score almost reached significance (OR 1.48, 0.99–2.22). Correct-
ing for time since diagnosis instead of symptom duration yielded
similar results (sCTX: OR 1.57, 1.16–2.13; PINP: OR 1.62, 1.12–
2.35).
The mSASSS correlated significantly with sCTX Z-score
(r=0.200, p = 0.016) and PINP Z-score (r=0.180, p = 0.030);
no relation was found with BALP Z-score (r=0.010, p = 0.910).
Bone Mineral Density and BTM
Of the 151 patients, 66 (44%) had lumbar spine and/or hip
BMD Z-score # 21 and 18 (12%) had BMD Z-score # 22.
Patients with low BMD (n= 66) had significantly higher sCTX Z-
scores than patients with normal BMD (median difference 0.53).
No significant difference was found in PINP and BALP Z-scores
(Figure 2). In addition, patients with low BMD had significantly
higher CRP levels and shorter disease duration (Table 2).
In univariable logistic regression, sCTX Z-score (OR: 1.35,
1.05–1.74) was significantly associated with the presence of low
BMD. The amount of variance explained by sCTX Z-score was
5.1%. The AUC of sCTX Z-score was 0.61 (0.52–0.70) to
discriminate between patients with low and normal BMD. This
relation remained significant (OR: 1.38, 1.04–1.83) after correct-
ing for CRP and symptom duration.
Combined Analysis
Both complete bridging and low BMD were present in 20 of 151
(13%) patients. 32 (21%) had only bridging, 46 (31%) had only low
BMD, and 53 (35%) did not have bridging or low BMD. sCTX Z-
score was significantly higher in patients with low BMD, bridging,
or both compared to patients without bridging and normal BMD.
Furthermore, patients with both bridging and low BMD had
significantly higher sCTX Z-scores than patients with only low
BMD (Figure 3).
Figure 1. Bone turnover in AS patients with $1 complete bridge (n=52), $1 non-bridging syndesmophyte (n=49), and without
syndesmophytes (n=50). A) bone resorption marker sCTX, B) bone formation marker PINP, C) bone formation marker BALP. Box-and-whisker plots
(Tukey): boxes indicate medians with interquartile ranges;+indicate means; whiskers indicate 1.5 times the interquartile distances; ? indicate outliers.
doi:10.1371/journal.pone.0099685.g001
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In univariable multinomial logistic regression, sCTX Z-score
was significantly associated with the presence of low BMD alone
(OR: 1.59), bridging alone (OR: 1.88), and bridging in combina-
tion with low BMD (OR: 2.51). The amount of variance explained
by sCTX Z-score was 14.4%. The AUC of sCTX Z-score was
0.78 (0.67–0.89) to discriminate between patients with bridging
plus low BMD and patients without bridging plus normal BMD.
After correcting for gender, symptom duration, and CRP,
sCTX Z-score remained significantly related to the presence of
low BMD alone (OR: 1.60), bridging alone (OR: 1.82), and
bridging in combination with low BMD (OR: 2.26) (Table 3). The
total amount of variance explained by the full model was 45.9%.
Correcting for BASDAI, ASDAS, or ESR instead of CRP yielded
similar results (data not shown).
Discussion
The present cross-sectional study within the GLAS cohort
showed that higher serum levels of bone resorption marker sCTX
and bone formation marker PINP were significantly associated
with the presence of complete bridging in AS patients with active
disease. The relation of sCTX with bridging remained statistically
significant after correcting for gender and disease duration. Our
finding that patients with bridging were more often male and had
longer disease duration is in accordance with earlier findings in
AS. [4,30,31].
In clinical studies concerning the monitoring of osteoporosis
treatment and fracture risk prediction, the use of sCTX and PINP,
both products of type I collagen, has been recommended. [32]
Neither sCTX nor PINP are specific to bone, but the highest
contributions are probably bone derived. BALP, an enzyme that
has a central role in the mineralization process after osteoid
forming, is specific for bone, but has some cross-reactivity with
liver isoform (up to 20%). Although PINP and BALP show smaller
circadian rhythm, sCTX was closer related to osteoproliferation
than PINP; the median difference in Z-score between AS patients
with and without bridging was 0.98 and 0.51, respectively.
Surprisingly, no significant association was found for BALP.
Previous studies searching for biomarkers that reflect structural
damage in AS have shown that higher serum levels of MMP-3
significantly predicted 2-year radiographic progression in multi-
variable analysis. [14] Furthermore, lower serum levels of Wnt
signalling pathway inhibitors sclerostin and dickkopf-1 were
significantly associated with 2-year radiographic progression in
univariable analysis. [15,16] Another candidate, cartilage turnover
marker urinary cross-linked telopeptide of type-II collagen
(uCTX-II) was found to be independently related to radiological
damage at baseline and 2-year radiological progression. However,
the amount of variance explained by uCTX-II was small (full
Table 2. Characteristics of AS patients with or without complete bridging and with low or normal BMD.
Bridginga No bridging Low BMDb Normal BMD
Number of patients 52 99 66 85
Gender (male) (n, %) 47 (90) 61 (62)* 51 (77) 57 (67)
Duration of symptoms (yrs) 24 (2–53) 11 (1–35)* 13 (2–47) 18 (1–53){
Time since diagnosis (yrs) 14 (0–44) 3 (0–26)* 7 (0–44) 6 (0–41)
HLA-B27+ (n, %) 43 (88) 77 (79) 50 (78) 70 (84)
Current smoking (n, %) 16 (47) 29 (39) 18 (36) 27 (46)
Current NSAID use (n, %) 40 (77) 68 (69) 50 (76) 58 (68)
BASDAI (range 0–10) 5.961.7 6.161.6 5.961.8 6.261.6
ASDASCRP 3.860.8 3.760.8 3.860.9 3.760.7
ESR (mm/h) 20 (3–76) 21 (2–90) 23 (2–90) 17 (2–76)
CRP (mg/l) 14 (2–99) 13 (2–70) 16 (2–99) 10 (2–64){
BASFI (range 0–10) 6.2 (1.1–9.7) 5.6 (0.4–9.3) 5.5 (0.4–9.7) 5.7 (0.5–9.3)
sCTX Z-score 0.43 (22.23–5.38) 20.55 (22.58–3.20)* 20.08 (21.89–4.01) 20.61 (22.58–5.38){
sCTX (pg/ml) 239.4 (31.0–618.7) 175.8 (13.4–657.1)* 227.6 (35.6–657.1) 160.3 (13.4–618.7){
PINP Z-score 0.55 (21.37–8.77) 0.04 (21.75–3.63)* 0.12 (21.56–3.63) 0.28 (21.75–8.77)
PINP (mg/l) 47.6 (17.9–132.5) 41.6 (16.0–101.5) 50.2 (16.4–101.5) 41.8 (16.0–132.5)
BALP Z-score 0.52 (21.73–9.68) 0.28 (22.59–10.38) 0.17 (21.64–10.38) 0.43 (22.59–9.68)
BALP (U/L) 18.2 (6.9–67.2) 17.6 (1.6–41.2) 18.3 (8.9–41.2) 17.5 (1.6–67.2)
mSASSS (range 0–72) 40 (11–72) 7 (1–29)* 10 (1–72) 15 (2–72){
LS BMD Z-score 0.0961.59 20.5261.40* 21.4760.93 0.6061.18{
Hip BMD Z-score 20.2560.92 20.2161.13 20.9760.76 0.3560.89{
Values are mean 6 SD or median (range) unless otherwise indicated.
aDefined as ankylosis of at least two vertebrae.
bDefined as lumbar spine and/or hip BMD Z-score # 21.
*p,0.05 compared to patients with at least one complete bridge.
{p,0.05 compared to patients with low BMD.
See Table 1 for abbreviations.
No significant differences in extra-articular manifestations or peripheral arthritis were found between patients with or without complete bridging and low or normal
BMD (data not shown).
doi:10.1371/journal.pone.0099685.t002
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model R2 was 6%). [18] In contrast to our findings, Vosse et al.
could not demonstrate a relation between uCTX-I and structural
damage. [18] The most likely explanation for this difference is that
measuring CTX in urine has more variation compared to serum
as well as that sCTX levels were not corrected for age and gender
in the former study.
Besides osteoproliferation, AS is characterized by bone loss,
which can lead to a reduction in BMD and/or vertebral fractures.
In the present study, a significant association between sCTX and
low BMD was found. Analyzing lumbar spine and hip BMD
separately, we found only a significant difference in sCTX for low
hip BMD (data not shown). The relation between CTX-I and low
hip BMD has been reported before. [17,18] Serum levels of PINP
and BALP were comparable between patients with normal and
low BMD. These findings are in accordance with two previous
studies, which also found no significant correlation between PINP
or BALP and BMD in small groups of AS patients. [33,34].
Finally, we analyzed the combination of excessive bone
formation (vertebral ankylosis) and bone loss (low BMD). sCTX
Z-score was significantly higher in AS patients with low BMD,
complete bridging, or both compared to patients without bridging
and normal BMD. Interestingly, these differences remained
significant after correcting for gender, disease duration, and
CRP, suggesting that serum levels of sCTX reflect bone-related
outcome in AS. The accuracy of sCTX Z-score to discriminate
between patients with bridging plus low BMD and patients
without bridging plus normal BMD was moderate (AUC of 0.78).
A striking finding was that AS patients without bridging and
normal BMD had a median sCTX Z-score of 20.85. Further
exploration of the reduction in this bone resorption marker in this
group of AS patients is needed.
With pre-analytical standardization of blood sampling as well as
standardization of assays, [32] sCTX and PINP meet most of the
requirements of the Outcome Measures in Rheumatology
Figure 2. Bone turnover in AS patients with low (n=66) and normal (n =85) BMD. A) bone resorption marker sCTX, B) bone formation
marker PINP, C) bone formation marker BALP. Box-and-whisker plots (Tukey): boxes indicate medians with interquartile ranges;+indicate means;
whiskers indicate 1.5 times the interquartile distances; ? indicate outliers.
doi:10.1371/journal.pone.0099685.g002
Figure 3. Bone resorption marker sCTX in AS patients with
complete bridging, low BMD or both. Box-and-whisker plots
(Tukey): boxes indicate medians with interquartile ranges;+indicate
means; whiskers indicate 1.5 times the interquartile distances; ? indicate
outliers. BS: complete bridging, OP: low BMD.
doi:10.1371/journal.pone.0099685.g003
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(OMERACT) validation criteria for soluble biomarkers reflecting
structural damage. [35] Regardless the variation in BTM levels
between individual patients, the present cross-sectional study
shows that serum levels of sCTX and PINP are higher in AS
patients with bridging. Furthermore, both BTM correlate signif-
icantly with mSASSS, the structural damage endpoint for AS.
These rather weak correlations can probably be explained by the
fact that the presence of erosions, sclerosis, and/or squaring can
already result in mSASSS scores up to 24, without evidence of
bony proliferation on radiographs. To exclude the influence of
these relatively minor radiographic changes, we used the presence
of complete bridging as measure of more advanced radiographic
damage in AS. Interestingly, BTM were found to be associated
with the presence of complete bridging, but not with the presence
of syndesmophytes. A possible explanation may be that syndes-
mophytes can vary in size and severity. Complete bridging is
considered as the final outcome (ankylosing of two vertebrae).
Although very interesting, our results should be interpreted with
some caution due to the cross-sectional design and only AS
patients with active and relatively long-standing disease were
analyzed. To confirm our results, further studies should include
also patients without active disease as well as patients in early
stages of the disease. TNF-a blocking agents have shown to be
very effective in controlling systemic inflammation and improving
clinical outcome in AS. [2] In addition, we found a significant
decrease in sCTX after starting TNF-a blocking therapy. [19] In
the present analysis, disease activity did not influence the
association between sCTX Z-score and the presence of complete
bridging or low BMD. However, BTM and inflammatory markers
in serum are systemic measurements and the relation with local
inflammatory processes was not investigated.
In 50 patients (25%), part of the data on BTM (n=10),
radiology (n = 38), and BMD (n= 15) was missing due to logistic
reasons and they were excluded from all analyses. Patient
characteristics were comparable between patients with and
without complete data, except for somewhat higher BASFI score
in patients without complete data. When including all available
data per analysis, similar results were found as in the complete case
analysis. Similar results were also observed after excluding patients
who used corticosteroids (data not shown).
Patients with complete bridging were identified to have
significantly longer disease duration and higher lumbar spine
BMD compared to patients without bridging. Hip BMD was
similar between both groups. On the other hand, patients with low
lumbar spine BMD had significantly shorter disease duration than
patients with normal BMD. These findings suggest that bridging
causes an overestimation in lumbar spine BMD measured by
DXA in patients with advanced AS. This is in line with our
previous finding that the difference between lumbar spine and hip
BMD correlated positively with disease duration. [11] Further-
more, Karberg et al. showed that in AS patients with short disease
duration (,5 years), low BMD was found more frequently in the
spine, whereas in patients with longer disease duration (.10
years), osteoporosis was more frequent found in the hip. [36] For
this reason, we used both lumbar spine and hip to define low BMD
in our study. However, since we analyzed a group of AS patients
with relatively long-standing disease (median symptom duration of
15 years), the percentage of patients with low BMD may be
underestimated. BMD Z-scores were used because of the young
age (mean 42 years) of the AS population [24].
The prevalence of low BMD found in our cohort was high
compared to the general population. Of the AS patients, 44% had
lumbar spine and/or hip BMD Z-score # 21 and 12% had BMD
Z-score # 22. Due to the small number of patients with BMD Z-
score # 22, separate analyses using this threshold could not be
performed, which may limit the clinical interpretation of our
results. Patients who used bisphosphonates (because of severe
osteoporosis) were excluded because of the large reduction in
BTM.
Conclusion
This cross-sectional analysis in AS patients with active disease
demonstrated that higher serum levels of sCTX, and to a lesser
extent PINP, are associated with the presence of complete
bridging. Higher serum levels of sCTX were also associated with
low BMD. Longitudinal studies are needed to confirm that BTM,
especially sCTX, can serve as objective markers for bone-related
outcome as well as to investigate whether BTM can predict spinal
radiographic progression and decrease in BMD in AS.
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Table 3. Multinomial regression analysis for the relation between bone resorption marker sCTX and the presence of complete
bridging and/or low BMD.
Low BMD Bridging Low BMD and bridging
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
sCTX Z-score 1.59 (1.90–2.31) 0.016 1.88 (1.26–2.81) 0.002 2.51 (1.61–3.90) ,0.001
sCTX Z-score (corrected model)` 1.60 (1.04–2.45) 0.032 1.82 (1.12–2.94) 0.015 2.26 (1.37–3.73) 0.002
Patients without bridging and normal BMD were used as reference category.
`Corrected for gender, symptom duration, and CRP.
See Tables 1 and 2 for abbreviations and definitions, respectively.
doi:10.1371/journal.pone.0099685.t003
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